Convertibles Calendar: Karyopharm to price $150 million convertibles

October 10

KARYOPHARM THERAPEUTICS INC.

• $150 million of convertible notes due 2025

• $22.5 million over-allotment option

• Price talk for 2.5% to 3% coupon, up 25%-30%

• J.P. Morgan Securities LLC and Leerink are joint bookrunners

• Non-callable until Oct. 15, 2022

• Proceeds will be used for launch of selinexor and support further clinical development of selinexor and two other pipeline drugs

• Newton, Mass.-based clinical-stage pharmaceutical company

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.